Human Papillomavirus in Young People Epidemiological Research 3 (HYPER3)

Monash University

Status: Enrolling

Conditions: Anal Cancer; HPV; HPV Infection; Men; Human Papillomavirus Infection; Cancer; HPV 16 Infection

Study type: Observational

Funder types: Other

Identifiers

NCT05587725

14/22

Details and patient eligibility

About

Anal cancer is overrepresented among gay, bisexual and other men who have sex with men (MSM), particularly those living with HIV. Australia was the first country to introduce a publicly funded national HPV vaccination program in 2007. This program was expanded to include schoolboys aged 12-13 years in 2013; with a 2-year catch-up for boys aged up to 15 years. In 2018, the 9-valent vaccine (covering genotypes 6/11/16/18/31/33/45/52/58) replaced the 4-valent vaccine in the national program.

The goal of the HYPER3 study is to determine the prevalence of anal, genital and oral HPV among 200 young gay and bisexual men aged 16-20 years who were eligible for the school-based 9-valent vaccination.

Participants will be required to complete a questionnaire and provide samples for HPV testing. No follow-up visits will be required.

Enrollment: 200 estimated patients

Sex: Male

Ages: 16 to 20 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Men aged 16 to 20 (i.e. men aged 16-18 years in 2023; men aged 16-19 years in 2024; and men aged 16-20 years in 2025 will be recruited. This is to ensure these men would have been eligible for the 9-valent school-based HPV program)
• Same-sex attracted
• Residing in Australia since 2018

Exclusion criteria

• Unable to complete all study requirements in English